BerGenBio Reports Second Quarter 2023 Financial Results
BERGEN, Norway, August 23, 2023 – BerGenBio ASA (OSE: BGBIO), a clinical-stage biopharmaceutical company developing novel, selective AXL kinase inhibitors for severe unmet medical needs, today announced financial results for the second quarter and first half ended June 30, 2023, and provided a business update. A briefing by BerGenBio's senior management team will take place at 10:45 am CEST today via a webcast presentation, followed by a Q&A session. Please see below for details. "For the second quarter we are pleased to report the outcomes of our cost-savings efforts and the